TransMedics Group - TMDX Stock Forecast, Price & News

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Trading Up 2.0 %

TMDX Stock traded up $0.91 during mid-day trading on Friday, hitting $46.94. The company had a trading volume of 341,935 shares, compared to its average volume of 561,970. TransMedics Group has a 12 month low of $10.00 and a 12 month high of $49.27. The company has a debt-to-equity ratio of 0.70, a quick ratio of 3.41 and a current ratio of 4.18. The stock's fifty day moving average price is $33.71 and its two-hundred day moving average price is $25.99.

TransMedics Group (NASDAQ:TMDX - Get Rating) last posted its quarterly earnings data on Monday, August 1st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative return on equity of 74.20% and a negative net margin of 92.76%. During the same quarter in the prior year, the company earned ($0.39) EPS. Equities analysts forecast that TransMedics Group will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of research analyst reports. Cowen increased their price objective on shares of TransMedics Group from $45.00 to $50.00 in a report on Tuesday, August 2nd. Cowen upped their price objective on TransMedics Group from $39.00 to $45.00 and gave the stock an "outperform" rating in a report on Tuesday, July 26th. JPMorgan Chase & Co. upgraded TransMedics Group from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $46.00 to $58.00 in a research note on Thursday, August 4th. Finally, Oppenheimer upped their price objective on TransMedics Group from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and an average target price of $46.00.

Insider Buying and Selling

In related news, Director James R. Tobin sold 48,515 shares of the firm's stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $35.00, for a total value of $1,698,025.00. Following the sale, the director now owns 302,106 shares in the company, valued at $10,573,710. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director James R. Tobin sold 48,515 shares of TransMedics Group stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $35.00, for a total transaction of $1,698,025.00. Following the sale, the director now owns 302,106 shares of the company's stock, valued at approximately $10,573,710. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John F. Carey sold 1,500 shares of the firm's stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $28.19, for a total value of $42,285.00. Following the transaction, the vice president now owns 379 shares of the company's stock, valued at approximately $10,684.01. The disclosure for this sale can be found here. Insiders have sold 151,814 shares of company stock valued at $5,633,336 over the last quarter. Corporate insiders own 8.70% of the company's stock.